<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130223012571N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-13</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>The effect of MIND diet on physical fitness</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of MIND diet on physical fitness and anthropometric indices in female high school students: a cluster randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>300</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72723</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: Among the high school girls' schools in Yazd that are eligible to enter the study, 6 schools are randomly selected using SPSS software. 6 envelopes containing intervention or control codes prepared in advance are provided to the investigators. After opening each envelope, the investigators identify each school. In each school, according to the assigned group, 50 students are randomly selected (by generating 50 random numbers and choosing from the list of students of each school) and enter the study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>High school girl students.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Mediterranean-DASH Diet Intervention for Neurodegenerative Delay                                                                              The MIND diet is a combination of the Mediterranean diet and DASH, which will be adjusted according to the ratio of macronutrients: 50-60% carbohydrates, 25-30% fat, and 15-20% protein for the intervention group. The MIND diet contains high amounts of green leafy vegetables and other vegetables, berries, nuts, olive oil, whole grains, fish, legumes, and poultry. Intervention 2: Control group: he usual diet which is similar to the usual Iranian diet with a macro-nutrient composition of 60-50% of carbohydrates, 25-30% of fats and 15-20% or proteins.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The general characteristics of the participants (without mentioning names and personal information) as well as the data for baseline and post-intervention values for primary and secondary outcomes will be made available to those interested after submitting the researchers' request and reviewing the principal investigators.

When:
The data will be available to the researchers when the related articles are published.

To whom:
The data will be available for all researchers interested in the subject.

Conditions:
Data will be available if the interested researcher(s) fills the proposal for a joint project and the sponsor of the study (Shahid Sadoughi University of Medical Sciences) confirms the protocol of the project.

Where to obtain:
he data can be obtained from:​Dr. Amin Salehi-Abargouei, Ph.D. in Nutrition Department of Nutrition Faculty of Public Health Sahid Sadoughi University of Medical Sciences Yazd, PO Code 8915173160 Iran Tel:+98-35-31492229 Fax:+98-35-38209119 Email: abargouei@ssu.ac.ir Alternate email: abargouei@gmail.com

How to obtain:
The interested investigators should provide a brief description of the data needed and their reason for asking the data by contacting the principal investigator. The principal investigator will assess the possibility of sharing the data and if applicable will ask for a joint proposal. The joint proposal will be sent to the vice chancellery for research, ShahidSadoughi University of Medical Sciences (the sponsor) and the data will be sent by the principal investigator if the sponsor confirms the cooperation.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Moghtaderi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Nutrition, Faculty of Public Health, Shahid Sadughi University of Medical Sciences, Alem Square, Yazd, Iran.</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>​8915173160</zip>
        <telephone>+98 35 3820 9100</telephone>
        <email>moghtaderi.fatemeh@gmial.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Amin Salehi-Abargouei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Nutrition, Faculty of Public Health, Shahid Sadughi University of Medical Sciences, Alem Square, Yazd, Iran.</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>​8915173160</zip>
        <telephone>+98 35 3820 9100</telephone>
        <email>abargouei@ssu.ac.ir</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>High school girls aged 15 to 17 years
Informed consent of participants and their parents
Having regular menstruation</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>17 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>cardiovascular diseases
History of liver and kidney disease
Suffering from cancer or a history of cancer
Having a known cardiovascular disease or a history of heart surgery
Having type 2 diabetes (fasting blood sugar above 126) or type 1 diabetes
Recipient of a special diet
Having any underlying disease
People who do professional sports or are athletes
Allergy to any of the components of the MIND diet
Obese people (over 97th percentile)
History of women's diseases and use of hormonal drugs</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Mediterranean-DASH Diet Intervention for Neurodegenerative Delay                                                                              The MIND diet is a combination of the Mediterranean diet and DASH, which will be adjusted according to the ratio of macronutrients: 50-60% carbohydrates, 25-30% fat, and 15-20% protein for the intervention group. The MIND diet contains high amounts of green leafy vegetables and other vegetables, berries, nuts, olive oil, whole grains, fish, legumes, and poultry.</i_keyword>
      <i_keyword>Control group: he usual diet which is similar to the usual Iranian diet with a macro-nutrient composition of 60-50% of carbohydrates, 25-30% of fats and 15-20% or proteins.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Weight. Timepoint: The beginning and end of the study (after three months). Method of measurement: A scale with an accuracy of 100 grams.</prim_outcome>
      <prim_outcome>Waist circumference. Timepoint: The beginning and end of the study (after three months). Method of measurement: tape measure with an accuracy of 0.5 cm.</prim_outcome>
      <prim_outcome>Body mass index. Timepoint: The beginning and end of the study (after three months). Method of measurement: The ratio of weight to the square of height.</prim_outcome>
      <prim_outcome>Percentage of fat mass. Timepoint: The beginning and end of the study (after three months). Method of measurement: body composition analyzer (Omron).</prim_outcome>
      <prim_outcome>Skeletal muscle percentage. Timepoint: The beginning and end of the study (after three months). Method of measurement: body composition analyzer (Omron).</prim_outcome>
      <prim_outcome>Cardiorespiratory fitness. Timepoint: The beginning and end of the study (after three months). Method of measurement: 20 m shuttle run test.</prim_outcome>
      <prim_outcome>Handgrip strength. Timepoint: The beginning and end of the study (after three months). Method of measurement: Handgrip.</prim_outcome>
      <prim_outcome>Anaerobic power. Timepoint: The beginning and end of the study (after three months). Method of measurement: Standing broad jump.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Depression score. Timepoint: The beginning and end of the study (after three months). Method of measurement: PHQ-9  and  DASS-21 questionnaires.</sec_outcome>
      <sec_outcome>Anxiety score. Timepoint: The beginning and end of the study (after three months). Method of measurement: GAD-7 and DASS-21 questionnaires.</sec_outcome>
      <sec_outcome>Stress score. Timepoint: The beginning and end of the study (after three months). Method of measurement: DASS-21 questionnaire.</sec_outcome>
      <sec_outcome>Overall health score. Timepoint: The beginning and end of the study (after three months). Method of measurement: GHQ questionnaire.</sec_outcome>
      <sec_outcome>The obtained score of premenstrual syndrome symptoms. Timepoint: The beginning and end of the study (after three months). Method of measurement: PSST questionnaire.</sec_outcome>
      <sec_outcome>The obtained score of menstrual distress. Timepoint: The beginning and end of the study (after three months). Method of measurement: MMDQ questionnaire.</sec_outcome>
      <sec_outcome>Sleep quality and quantity. Timepoint: The beginning and end of the study (after three months). Method of measurement: Pittsburgh Sleep Quality Index (PSQI).</sec_outcome>
      <sec_outcome>Mental health. Timepoint: The beginning and end of the study (after three months). Method of measurement: SDQ questionnaire.</sec_outcome>
      <sec_outcome>Health-related quality of life. Timepoint: The beginning and end of the study (after three months). Method of measurement: SF-36 questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-09-11</approval_date>
        <contact_name>Ethics committee of Shahid Sadoughi University of Medical Sciences Yazd</contact_name>
        <contact_address>Faculty of Public Health, Shahid Sadughi University of Medical Sciences, Alem Square, Yazd, Iran. Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
